Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Editas Medicine, Inc. before investing.

In this article, we go over a few key elements for understanding Editas Medicine, Inc.’s stock price such as:

• Editas Medicine, Inc.’s current stock price and volume
• Why Editas Medicine, Inc.’s stock price changed recently
• Upgrades and downgrades for EDIT from analysts
• EDIT’s stock price momentum as measured by its relative strength

About Editas Medicine, Inc. (EDIT)

Before we jump into Editas Medicine, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Want to learn more about Editas Medicine, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Editas Medicine, Inc..

Editas Medicine, Inc.’s Stock Price as of Market Close

As of April 29, 2026, 12:16 PM, CST, Editas Medicine, Inc.’s stock price was $2.830.

Editas Medicine, Inc. is down 7.52% from its previous closing price of $3.060.

During the last market session, Editas Medicine, Inc.’s stock traded between $2.820 and $3.060. Currently, there are approximately 97.26 million shares outstanding for Editas Medicine, Inc..

Editas Medicine, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Editas Medicine, Inc. Stock Price History

Editas Medicine, Inc.’s (EDIT) price is currently up 14.57% so far this month.

During the month of April, Editas Medicine, Inc.’s stock price has reached a high of $3.650 and a low of $2.500.

Over the last year, Editas Medicine, Inc. has hit prices as high as $4.537 and as low as $1.290. Year to date, Editas Medicine, Inc.’s stock is up 38.05%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Editas Medicine, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 28, 2026, there were 0 analysts who downgraded Editas Medicine, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Editas Medicine, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Editas Medicine, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Editas Medicine, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Editas Medicine, Inc. (EDIT) by visiting AAII Stock Evaluator.

Relative Price Strength of Editas Medicine, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 28, 2026, Editas Medicine, Inc. has a weighted four-quarter relative price strength of 22.25%, which translates to a Momentum Score of 91 and is considered to be Very Strong.

Want to learn more about how Editas Medicine, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Editas Medicine, Inc. Stock Price: Bottom Line

As of April 29, 2026, Editas Medicine, Inc.’s stock price is $2.830, which is down 7.52% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Editas Medicine, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.